Anticancer agent ABT-737 possesses anti-atopic dermatitis activity via blockade of caspase-1 in atopic dermatitis in vitro and in vivo models.

Hyun-Ja JeongKa-Jung RyuHyung-Min Kim

Published in: Immunopharmacology and immunotoxicology (2018)

ABT-737 elicited an anti-AD activity via suppression of caspase-1 activation in AD in vitro and in vivo models. Therefore, this study provides important information regarding the use of anticancer drugs for controlling allergic inflammatory diseases.

Keyphrases

atopic dermatitis
cell death
induced apoptosis
oxidative stress
endoplasmic reticulum stress
drug induced
allergic rhinitis